These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15083593)

  • 1. Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.
    Gilbert RE; Douglas SA; Krum H
    Curr Opin Investig Drugs; 2004 Mar; 5(3):276-82. PubMed ID: 15083593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging roles of urotensin-II in cardiovascular disease.
    Russell FD
    Pharmacol Ther; 2004 Sep; 103(3):223-43. PubMed ID: 15464591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urotensin II: a cardiovascular and renal update.
    Zoccali C; Mallamaci F
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):199-204. PubMed ID: 18277155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urotensin II: the old kid in town.
    Onan D; Hannan RD; Thomas WG
    Trends Endocrinol Metab; 2004; 15(4):175-82. PubMed ID: 15109617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of urotensin II in cardiovascular and renal physiology and diseases.
    Zhu YC; Zhu YZ; Moore PK
    Br J Pharmacol; 2006 Aug; 148(7):884-901. PubMed ID: 16783414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties and functional determinants of the urotensin II receptor.
    Proulx CD; Holleran BJ; Lavigne P; Escher E; Guillemette G; Leduc R
    Peptides; 2008 May; 29(5):691-9. PubMed ID: 18155322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography.
    Disa J; Floyd LE; Edwards RM; Douglas SA; Aiyar NV
    Peptides; 2006 Jun; 27(6):1532-7. PubMed ID: 16290260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urotensin II: its function in health and its role in disease.
    Ong KL; Lam KS; Cheung BM
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):65-75. PubMed ID: 15883758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of urotensin II in human pathophysiology].
    Piech J; Skoczylas A
    Wiad Lek; 2008; 61(10-12):277-82. PubMed ID: 19323069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urotensin II and atherosclerosis.
    Loirand G; Rolli-Derkinderen M; Pacaud P
    Peptides; 2008 May; 29(5):778-82. PubMed ID: 17933432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14.
    Ames RS; Sarau HM; Chambers JK; Willette RN; Aiyar NV; Romanic AM; Louden CS; Foley JJ; Sauermelch CF; Coatney RW; Ao Z; Disa J; Holmes SD; Stadel JM; Martin JD; Liu WS; Glover GI; Wilson S; McNulty DE; Ellis CE; Elshourbagy NA; Shabon U; Trill JJ; Hay DW; Ohlstein EH; Bergsma DJ; Douglas SA
    Nature; 1999 Sep; 401(6750):282-6. PubMed ID: 10499587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A vasoactive peptide: urotensin II].
    Liu GQ; Zeng ZP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):525-8. PubMed ID: 16178453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.
    Douglas SA; Dhanak D; Johns DG
    Trends Pharmacol Sci; 2004 Feb; 25(2):76-85. PubMed ID: 15102493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships of urotensin II and URP.
    Leprince J; Chatenet D; Dubessy C; Fournier A; Pfeiffer B; Scalbert E; Renard P; Pacaud P; Oulyadi H; Ségalas-Milazzo I; Guilhaudis L; Davoust D; Tonon MC; Vaudry H
    Peptides; 2008 May; 29(5):658-73. PubMed ID: 17931747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-supported purification of the urotensin-II receptor.
    Du AT; Onan D; Dinh DT; Lew MJ; Ziogas J; Aguilar MI; Pattenden LK; Thomas WG
    Mol Pharmacol; 2010 Oct; 78(4):639-47. PubMed ID: 20647393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human urotensin II as a link between hypertension and coronary artery disease.
    Watanabe T; Kanome T; Miyazaki A; Katagiri T
    Hypertens Res; 2006 Jun; 29(6):375-87. PubMed ID: 16940699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
    Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
    J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout.
    Wang ZJ; Shi LB; Xiong ZW; Zhang LF; Meng L; Bu DF; Tang CS; Ding WH
    Peptides; 2006 Apr; 27(4):858-63. PubMed ID: 16325305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of urotensin II in atherosclerotic cardiovascular diseases.
    Pakala R
    Cardiovasc Revasc Med; 2008; 9(3):166-78. PubMed ID: 18606380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1.
    Hirose T; Takahashi K; Mori N; Nakayama T; Kikuya M; Ohkubo T; Kohzuki M; Totsune K; Imai Y
    Peptides; 2009 Jun; 30(6):1124-9. PubMed ID: 19463745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.